INNOCAN PHARMA CORPORATION financial statements, including revenue, expenses, profit, and loss
The total revenue of IP4 for the last quarter is 6.24 M EUR, and it's 37.07% higher compared to the previous quarter. The net income of Q1 24 is -1.63 M EUR.